← Eichor
Study identifier: NCT05474430 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity

Condition: Carrier State · Respiratory Infections  ·  Sponsor: Philip Polgreen

PhaseN/A
Planned participants160
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays. An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19. The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.

This description comes directly from the study's public registry record.

Talk to the study team

Philip M Polgreen, MD  ·  (319) 384-6194  ·  philip-polgreen@uiowa.edu

Shelby L Francis, PhD  ·  319-678-8037  ·  shelby-francis@uiowa.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Iowa Hospitals and ClinicsIowa City, Iowa, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05474430